BridgeBio Financial Statements (BBIO)
|
|
|
|
Report date
|
|
|
03.03.2020 |
25.02.2021 |
25.02.2022 |
23.02.2023 |
22.02.2024 |
|
30.09.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
40.6 |
8.25 |
69.7 |
77.6 |
9.30 |
|
217.8 |
|
Operating Income, bln rub |
|
|
-266.2 |
-474.5 |
-579.7 |
-471.9 |
-607.4 |
|
-541.0 |
|
EBITDA, bln rub |
? |
|
-279.8 |
-465.7 |
-533.8 |
-397.4 |
-565.5 |
|
-350.3 |
|
Net profit, bln rub |
? |
|
-260.4 |
-483.9 |
-639.3 |
-494.0 |
-643.2 |
|
-438.9 |
|
|
OCF, bln rub |
? |
|
-253.6 |
-399.7 |
-497.9 |
-419.5 |
-527.7 |
|
-450.2 |
|
CAPEX, bln rub |
? |
|
5.14 |
7.52 |
48.2 |
6.32 |
1.31 |
|
6.11 |
|
FCF, bln rub |
? |
|
-258.7 |
-407.2 |
-546.2 |
-425.8 |
-529.0 |
|
-456.3 |
|
Dividend payout, bln rub
|
|
|
0.997 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
304.3 |
482.7 |
646.3 |
546.1 |
614.2 |
|
754.3 |
|
Cost of production, bln rub |
|
|
2.50 |
3.09 |
3.11 |
3.43 |
2.45 |
|
3.69 |
|
R&D, bln rub |
|
|
209.9 |
337.0 |
454.1 |
402.9 |
455.7 |
|
506.3 |
|
Interest expenses, bln rub |
|
|
8.77 |
36.7 |
46.8 |
80.4 |
81.3 |
|
89.7 |
|
|
Assets, bln rub |
|
|
631.7 |
703.6 |
1 013 |
623.0 |
546.4 |
|
665.0 |
|
Net Assets, bln rub |
? |
|
408.5 |
57.9 |
-870.4 |
-1 255 |
-1 354 |
|
-1 230 |
|
Debt, bln rub |
|
|
99.8 |
495.8 |
1 726 |
1 724 |
1 740 |
|
1 730 |
|
Cash, bln rub |
|
|
577.1 |
607.1 |
787.5 |
428.3 |
434.9 |
|
266.3 |
|
Net debt, bln rub |
|
|
-477.3 |
-111.3 |
938.7 |
1 295 |
1 305 |
|
1 463 |
|
|
Ordinary share price, rub |
|
|
35.1 |
71.1 |
16.7 |
7.62 |
40.4 |
|
26.9 |
|
Number of ordinary shares, mln |
|
|
105.1 |
118.0 |
144.4 |
147.5 |
162.8 |
|
188.5 |
|
|
Market cap, bln rub |
|
|
3 684 |
8 391 |
2 408 |
1 124 |
6 572 |
|
5 075 |
|
EV, bln rub |
? |
|
3 206 |
8 279 |
3 347 |
2 419 |
7 877 |
|
6 538 |
|
Book value, bln rub |
|
|
408 |
58 |
-915 |
-1 283 |
-1 381 |
|
-1 230 |
|
|
EPS, rub |
? |
|
-2.48 |
-4.10 |
-4.43 |
-3.35 |
-3.95 |
|
-2.33 |
|
FCF/share, rub |
|
|
-2.46 |
-3.45 |
-3.78 |
-2.89 |
-3.25 |
|
-2.42 |
|
BV/share, rub |
|
|
3.89 |
0.49 |
-6.34 |
-8.70 |
-8.48 |
|
-6.52 |
|
|
EBITDA margin, % |
? |
|
-689.9% |
-5 646% |
-765.7% |
-511.9% |
-6 078% |
|
-160.8% |
|
Net margin, % |
? |
|
-642.1% |
-5 866% |
-917.0% |
-636.2% |
-6 914% |
|
-201.5% |
|
FCF yield, % |
? |
|
-7.02% |
-4.85% |
-22.7% |
-37.9% |
-8.05% |
|
-8.99% |
|
ROE, % |
? |
|
-63.8% |
-835.7% |
73.4% |
39.4% |
47.5% |
|
35.7% |
|
ROA, % |
? |
|
-41.2% |
-68.8% |
-63.1% |
-79.3% |
-117.7% |
|
-66.0% |
|
|
P/E |
? |
|
-14.1 |
-17.3 |
-3.77 |
-2.27 |
-10.2 |
|
-11.6 |
|
P/FCF |
|
|
-14.2 |
-20.6 |
-4.41 |
-2.64 |
-12.4 |
|
-11.1 |
|
P/S |
? |
|
90.8 |
1 017 |
34.5 |
14.5 |
706.4 |
|
23.3 |
|
P/BV |
? |
|
9.02 |
144.9 |
-2.63 |
-0.88 |
-4.76 |
|
-4.13 |
|
EV/EBITDA |
? |
|
-11.5 |
-17.8 |
-6.27 |
-6.09 |
-13.9 |
|
-18.7 |
|
Debt/EBITDA |
|
|
1.71 |
0.24 |
-1.76 |
-3.26 |
-2.31 |
|
-4.18 |
|
|
R&D/CAPEX, % |
|
|
4 086% |
4 483% |
941.3% |
6 374% |
34 894% |
|
8 292% |
|
|
CAPEX/Revenue, % |
|
|
12.7% |
91.1% |
69.2% |
8.14% |
14.0% |
|
2.80% |
|
| BridgeBio shareholders |
